Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
58 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | active not recruiting | Phase 3 | 726 | mAbxience Research S.L.INDUSTRY | 24 | Sep 10, 2026 | clinicaltrials |
| NCT05645107 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma(EXCELL) | recruiting | Phase 3 | 386 | Grifols Therapeutics LLC |
| 8 |
| Jul 29, 2026 |
| clinicaltrials |
| NCT03456076 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 257 | Hoffmann-La RocheINDUSTRY | 27 | Jul 15, 2026 | clinicaltrials |
| NCT06348199 | A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 555 | Samsung Bioepis Co., Ltd.INDUSTRY | 14 | Jul 7, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT02075840 | A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants(ALEX) | completed | Phase 3 | 303 | Hoffmann-La RocheINDUSTRY | 29 | May 29, 2026 | clinicaltrials |
| NCT05907122 | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | completed | Phase 3 | 256 | AmgenINDUSTRY | 22 | Mar 27, 2026 | clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT06054555 | A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | active not recruiting | Phase 3 | 633 | AmgenINDUSTRY | 31 | Jan 12, 2026 | clinicaltrials |
| NCT03371017 | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer(IMpassion132) | completed | Phase 3 | 595 | Hoffmann-La RocheINDUSTRY | 28 | Nov 12, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | completed | Phase 3 | 1,095 | Hoffmann-La RocheINDUSTRY | 38 | Mar 4, 2024 | clinicaltrials |
| NCT02617485 | MabionCD20 Compared to MabThera in Lymphoma Patients(MADILYM) | completed | Phase 3 | 143 | Mabion SAINDUSTRY | 7 | Oct 25, 2023 | clinicaltrials |
| NCT02420821 | A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)(IMmotion151) | completed | Phase 3 | 915 | Hoffmann-La RocheINDUSTRY | 21 | Jan 30, 2023 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
| NCT02162667 | Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer | completed | Phase 3 | 562 | CelltrionINDUSTRY | 22 | Aug 3, 2022 | clinicaltrials |
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | completed | Phase 3 | 902 | Hoffmann-La RocheINDUSTRY | 40 | Jul 19, 2022 | clinicaltrials |
| NCT02340221 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy(SANDPIPER) | terminated | Phase 3 | 631 | Hoffmann-La RocheINDUSTRY | 28 | Jul 12, 2022 | clinicaltrials |
| NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 3 | 361 | Hoffmann-La RocheINDUSTRY | 14 | Jun 21, 2022 | clinicaltrials |
| NCT00920816 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | completed | Phase 3 | 492 | PfizerINDUSTRY | 14 | May 6, 2022 | clinicaltrials |
| NCT04633564 | MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC | completed | Phase 3 | 671 | Mylan Pharmaceuticals IncINDUSTRY | 17 | Mar 16, 2022 | clinicaltrials |
| NCT02810457 | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer(AVANA) | completed | Phase 3 | 731 | Centus Biotherapeutics LimitedINDUSTRY | 24 | Mar 10, 2022 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation IncNETWORK | 40 | Sep 10, 2020 | clinicaltrials |
| NCT00600340 | 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab(TURANDOT) | completed | Phase 3 | 564 | Central European Cooperative Oncology GroupOTHER | 12 | Dec 30, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT00917384 | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | completed | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 30 | Sep 25, 2019 | clinicaltrials |
| NCT00191126 | Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC | completed | Phase 3 | 263 | Eli Lilly and CompanyINDUSTRY | 15 | Sep 12, 2019 | clinicaltrials |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT01767155 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer(ZoptEC) | completed | Phase 3 | 511 | AEterna ZentarisINDUSTRY | 22 | Jul 31, 2018 | clinicaltrials |
| NCT02557035 | An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting | completed | Phase 3 | 441 | Helsinn Healthcare SAINDUSTRY | 9 | Jun 20, 2018 | clinicaltrials |
| NCT01307397 | A Study of Vemurafenib in Participants With Metastatic Melanoma | completed | Phase 3 | 3,219 | Hoffmann-La RocheINDUSTRY | 44 | Dec 18, 2017 | clinicaltrials |
| NCT01163253 | A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis | terminated | Phase 3 | 2,867 | PfizerINDUSTRY | 36 | Jun 26, 2017 | clinicaltrials |
| NCT00806819 | Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC | completed | Phase 3 | 718 | Boehringer IngelheimINDUSTRY | 32 | Feb 2, 2017 | clinicaltrials |
| NCT01450696 | A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer(HELOISE) | terminated | Phase 3 | 296 | Hoffmann-La RocheINDUSTRY | 25 | Nov 28, 2016 | clinicaltrials |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | completed | Phase 3 | 3,222 | SanofiINDUSTRY | 42 | Nov 15, 2016 | clinicaltrials |
| NCT00829166 | A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer(EMILIA) | completed | Phase 3 | 991 | Hoffmann-La RocheINDUSTRY | 27 | Oct 31, 2016 | clinicaltrials |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC(Galaxy 2) | terminated | Phase 3 | 696 | Synta Pharmaceuticals Corp.INDUSTRY | 20 | Jul 1, 2016 | clinicaltrials |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | completed | Phase 3 | 683 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 26 | May 26, 2016 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT00528567 | BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer | completed | Phase 3 | 2,591 | Hoffmann-La RocheINDUSTRY | 40 | Sep 4, 2015 | clinicaltrials |
| NCT00391092 | A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. | completed | Phase 3 | 424 | Hoffmann-La RocheINDUSTRY | 16 | Aug 28, 2015 | clinicaltrials |
| NCT00440310 | Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases | completed | Phase 3 | 483 | Light Sciences OncologyINDUSTRY | 13 | Aug 25, 2015 | clinicaltrials |
| NCT00293124 | Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors | completed | Phase 3 | 125 | Central European Cooperative Oncology GroupOTHER | 10 | Aug 13, 2015 | clinicaltrials |
| NCT00457691 | Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 768 | PfizerINDUSTRY | 34 | Mar 30, 2015 | clinicaltrials |
Data updated 19 days agoSource updated unknownsource: clinicaltrials